GRAIL, Inc. (BMV:GRAL)

Market Cap	67.26B +246.0%
Revenue (ttm)	2.60B +20.5%
Net Income	-7.45B
EPS	-213.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Average Volume	389
Open	1,785.00
Previous Close	1,828.00
Day's Range	1,785.00 - 1,785.00
52-Week Range	606.20 - 1,828.00
Beta	n/a
RSI	81.37
Earnings Date	Feb 20, 2026

About GRAIL

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2015
• Employees: 1,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GRAL

Financial Performance

In 2024, GRAIL's revenue was $125.60 million, an increase of 34.90% compared to the previous year's $93.11 million. Losses were -$2.03 billion, 38.3% more than in 2023.

Financial numbers in USD